Academic Journal
Q1Lancet Microbe
About Lancet Microbe
Lancet Microbe is a scholarly journal published by Elsevier Ltd. SCImago 2025 places it in Q1 with an SJR of 5.192 and an H-index of 67.
Its listed coverage is 2020-2026 and its research categories include Infectious Diseases (Q1); Microbiology (Q1); Microbiology (medical) (Q1); Virology (Q1). The 2025 dataset reports 246 documents and 5071 citations across the latest three-year reporting window.
The Lancet Microbe is a peer-reviewed, open-access medical journal that focuses exclusively on microbiology and its implications for global health. As part of the renowned Lancet family, The Lancet Microbe delivers high-quality research articles, reviews, and commentaries that address urgent issues in microbial science, including infectious diseases, antimicrobial resistance, diagnostics, and pathogen-host interactions.
Launched in 2020, The Lancet Microbe quickly established itself as a critical platform for microbiologists, epidemiologists, clinicians, and public health professionals. With its strong emphasis on scientific rigor, global relevance, and open-access publishing, the journal aims to support evidence-based decision-making in health systems worldwide.
What Does The Lancet Microbe Cover?
The Lancet Microbe publishes original research and expert analysis across a wide range of microbiology-related topics. These include:
-
Antimicrobial resistance (AMR): The journal features pioneering studies on resistance mechanisms, global surveillance data, and strategies to combat AMR, a growing threat to public health.
-
Emerging infectious diseases: Research on newly discovered pathogens, pandemic preparedness, and viral evolution is regularly featured.
-
Microbiome science: Articles explore the human microbiome’s role in health, disease prevention, and potential therapies.
-
Diagnostic innovations: The journal showcases advances in diagnostic tools and laboratory methods for detecting infectious diseases.
-
Vaccines and therapeutics: Groundbreaking research on vaccine development, drug discovery, and treatment options is a core focus.
A Global Perspective on Microbial Science
What distinguishes The Lancet Microbe from other microbiology journals is its global approach to research. The journal actively encourages submissions from low- and middle-income countries and prioritizes studies that address health disparities and region-specific microbial threats. It plays a vital role in shaping health policy through scientifically grounded content accessible to international audiences.
Open Access and Editorial Excellence
As an open-access medical journal, The Lancet Microbe ensures that all its published research is freely available to readers worldwide. This open-access model promotes equity in science, allowing researchers, healthcare providers, and policymakers unrestricted access to cutting-edge data and expert perspectives.
The journal maintains a rigorous peer-review process and upholds the highest standards of scientific publishing. With a diverse editorial board composed of leading experts in microbiology, infectious disease, immunology, and global health, the journal guarantees authoritative and timely content.
Why The Lancet Microbe Matters
In an age where microbial threats can spark global crises, The Lancet Microbe serves as a trusted resource for the scientific and medical communities. It supports innovation, drives collaboration, and amplifies research that can save lives and protect public health on a global scale.
Whether you are a microbiologist, infectious disease researcher, or public health leader, The Lancet Microbe offers the insights and evidence you need to stay at the forefront of microbial science.
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
The Lancet Microbe is a leading open-access journal dedicated to publishing high-impact research in microbiology with a clear focus on human health. As a member of the esteemed Lancet journal family, The Lancet Microbe fills a vital niche by providing a global platform for innovative studies on pathogens, microbial communities, and host-microbe interactions. The journal’s broad and interdisciplinary scope allows it to serve as a critical resource for microbiologists, infectious disease specialists, epidemiologists, and public health professionals.
Comprehensive Scope of The Lancet Microbe
The scope of The Lancet Microbe covers the full spectrum of microbiological research that is relevant to human health. The journal welcomes submissions on a variety of topics, including but not limited to:
1. Antimicrobial Resistance (AMR)
One of the journal’s core areas of focus is antimicrobial resistance, a growing global health crisis. The Lancet Microbe publishes original research on the mechanisms of AMR, surveillance studies, resistance gene mapping, and strategies for mitigation. The journal also explores the policy implications of AMR and promotes cross-disciplinary collaboration to address this urgent threat.
2. Infectious Disease Pathogenesis
The journal features research on the biology of pathogens—bacteria, viruses, fungi, and parasites—and their role in causing human disease. Studies on pathogen evolution, transmission dynamics, and virulence factors are central to its scope.
3. Host–Microbe Interactions
Understanding how microbes interact with human hosts is key to combating infectious diseases. The Lancet Microbe encourages submissions that explore molecular and cellular mechanisms of host response, immune evasion, and inflammation, as well as the microbiome’s influence on health and disease.
4. Diagnostics and Surveillance
The journal supports innovation in microbial diagnostics, including molecular testing, rapid detection technologies, and laboratory tools that improve disease surveillance. These advances are crucial for early outbreak detection, clinical decision-making, and public health interventions.
5. Microbiome and Health
The role of the human microbiome in modulating immune responses, influencing metabolism, and preventing disease is a growing area of interest. The Lancet Microbe provides a platform for microbiome studies with clinical and therapeutic relevance.
6. Vaccines and Therapeutics
Research on the development, effectiveness, and deployment of vaccines and antimicrobial treatments falls within the journal’s scope. This includes studies on novel drug targets, resistance mechanisms, and clinical trials related to infectious diseases.
Global and Inclusive Research
The Lancet Microbe prioritizes research with global significance, especially studies from low- and middle-income countries (LMICs) where the burden of infectious disease is often highest. The journal encourages submissions that highlight regional challenges, local surveillance efforts, and equitable solutions to global microbiological threats.
Recent Research Articles
Latest publications matched automatically by ISSN.
Mechanisms underlying rheumatic heart disease immune-mediated pathogenesis: T-cell responses, cytokine networks, and immune dysregulation as drivers of valvular injury
Adrien Lupieri, Juan Manuel Diaz, Thayse Batista Moreira, Adriana Jacaúna et al.
2026-09 · DOI: 10.1016/j.lanmic.2026.101499HIV, hepatitis, and STIs need renewed commitment
The Lancet Microbe
2026-09 · DOI: 10.1016/j.lanmic.2026.101541Differential success of human papillomavirus vaccination in people living with HIV and solid organ transplant recipients: lessons for vaccine design in immunocompromised individuals
Nathalie Ghorra, Deborah Konopnicki, Nicolas Dauby
2026-09 · DOI: 10.1016/j.lanmic.2026.101527WHO target product profiles for dengue therapeutics: an interdisciplinary analysis of ethical, regulatory, and implementation considerations
Tess Johnson, Shanghavie Loganathan, Euzebiusz Jamrozik, Michael J Parker et al.
2026-09 · DOI: 10.1016/j.lanmic.2026.101466Advancing Group A Streptococcus vaccines: barriers, models, and the path to rheumatic fever prevention
Mark J Walker, Stephan Brouwer
2026-09 · DOI: 10.1016/j.lanmic.2026.101495Five decades of pneumococcal meningitis in Spain: a single-centre, clinical and genomic, retrospective, observational study
Sara Calvo-Silveria, Aida González-Díaz, Carmen Cabellos, Alannah C King et al.
2026-09 · DOI: 10.1016/j.lanmic.2026.101471Bacterial co-detection in individuals with acute respiratory infections through a direct-to-consumer platform in China: a retrospective cross-sectional study
Chunyan Xiang, Jingya Li, Mengwei Yan, Shuyu Deng et al.
2026-09 · DOI: 10.1016/j.lanmic.2026.101502Accelerating the clinical development of treatments for dengue: WHO dengue therapeutics landscape analysis and target product profiles
Xin Hui S Chan, Anna P Durbin, Gathsaurie Neelika Malavige, Fausto Baldanti et al.
2026-09 · DOI: 10.1016/j.lanmic.2026.101451Shigellosis outbreak in Kerala
Priya Venkatesan
2026-09 · DOI: 10.1016/j.lanmic.2026.101533Home or hospital birth: a 3-year microbiota follow-up
Miloš Stojanov, Floriane Savoy, David Baud
2026-09 · DOI: 10.1016/j.lanmic.2026.101526Burden and genomic characterisation of Shigella-associated diarrhoea in children younger than 5 years in Lusaka, Zambia: a prospective cohort study
Mwelwa Chibuye, Vanessa C Harris, Jaime Brizuela, Samuel Bosomprah et al.
2026-08 · DOI: 10.1016/j.lanmic.2026.101408Widespread circulation of Alongshan virus in Austria and serological evidence for infection in humans: a nationwide molecular and serological observational study
David M Florian, Paul Jetzinger, Anna-Margarita Schötta, Iris Medits-Weiss et al.
2026-08 · DOI: 10.1016/j.lanmic.2026.101404Assessment of dried blood spot and umbilical cord blood samples for the quantification of maternally transferred IgG against the group B streptococcal alpha-like surface proteins in neonates at Kolding Hospital, Denmark: a proof-of-concept, cross-sectional study
May Murra, Tom Hall, Tine Brink Henriksen, Mohammed Rohi Khalil et al.
2026-08 · DOI: 10.1016/j.lanmic.2026.101409Wastewater-based sequencing of respiratory syncytial virus to investigate lineage dynamics and antigenic site mutations: a retrospective genomic epidemiology study
Jolinda de Korne-Elenbaas, Auguste Rimaite, Ivan Topolsky, David Dreifuss et al.
2026-08 · DOI: 10.1016/j.lanmic.2026.101355Female genital schistosomiasis in migrant women: diagnostic challenges in non-endemic settings
Tamara Ursini, Salvatore Scarso, Francesco Rizzolo, Anna Stepniewska et al.
2026-08 · DOI: 10.1016/j.lanmic.2026.101520Transmission dynamics of Andes virus and implications for outbreak monitoring
Jason R Andrews, Isaac I Bogoch
2026-08 · DOI: 10.1016/j.lanmic.2026.101469Profiling the dynamics of maternally acquired and infection-induced antibodies against influenza B in early childhood: a longitudinal paired mother–infant cohort study from southern China
Zeyao Zhao, Junbo Chen, Chao Han, Wei Wang et al.
2026-08 · DOI: 10.1016/j.lanmic.2026.101490Dual β-lactam therapy against high-risk Pseudomonas aeruginosa isolates: a dynamic in-vitro infection model study integrating population genomics with quantitative systems pharmacology modelling and simulations
Siobhonne K J Breen, Sara Cortés-Lara, Jessica R Tait, Kate E Rogers et al.
2026-08 · DOI: 10.1016/j.lanmic.2026.101364Serum neutralisation of H5N1 clade 2.3.4.4b influenza is largely mediated by neuraminidase-directed antibodies
Manoj S Nair, Hsiang Hong, Sue Chong, Yaoxing Huang et al.
2026-08 · DOI: 10.1016/j.lanmic.2026.101431Saliva versus lesion swabs for PCR diagnosis of acute-phase clade Ib mpox in Uganda: a prospective matched hospital cohort study
Jennifer Serwanga, Raymond Ernest Kaweesa, Deborah Mukisa, Geoffrey Odoch et al.
2026-08 · DOI: 10.1016/j.lanmic.2026.101395Reviews
Community Reviews
Version History
April 20, 2025 at 6:08 pm
April 20, 2025